Organon Balance Sheet Health
Financial Health criteria checks 1/6
Organon has a total shareholder equity of $144.0M and total debt of $8.7B, which brings its debt-to-equity ratio to 6011.1%. Its total assets and total liabilities are $12.2B and $12.0B respectively. Organon's EBIT is $1.3B making its interest coverage ratio 2.6. It has cash and short-term investments of $704.0M.
Key information
6,011.1%
Debt to equity ratio
US$8.66b
Debt
| Interest coverage ratio | 2.6x |
| Cash | US$704.00m |
| Equity | US$144.00m |
| Total liabilities | US$12.01b |
| Total assets | US$12.15b |
Recent financial health updates
Recent updates
Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis
Sep 19These 4 Measures Indicate That Organon (NYSE:OGN) Is Using Debt In A Risky Way
Sep 13
Organon & Co.: Cheap With Caveats
Aug 22Organon (NYSE:OGN) Will Pay A Dividend Of $0.28
Aug 09Insufficient Growth At Organon & Co. (NYSE:OGN) Hampers Share Price
Aug 07Organon: Upcoming Q2 Earnings Can Sustain Upward Momentum
Jul 30Organon & Co.'s (NYSE:OGN) CEO Might Not Expect Shareholders To Be So Generous This Year
May 29Organon's (NYSE:OGN) Solid Profits Have Weak Fundamentals
May 10Four Reasons Why Organon Stock Is A Good Buy
May 07Little Excitement Around Organon & Co.'s (NYSE:OGN) Earnings
Apr 21Organon Stock Is Still Worth A Look
Feb 24Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28
Feb 19Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last
Feb 16Organon: What I'm Looking For In This 8% Yield In 2024
Jan 03High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued
Dec 19Organon: It's Darkest Before The Dawn
Nov 30Organon: Poor Q3 Earnings Make Bear Case, But Dividend Is Saving Grace
Nov 07Organon (NYSE:OGN) Has Affirmed Its Dividend Of $0.28
Nov 05Organon: The Federal Reserve Black Swan (Rating Upgrade)
Oct 046% Yield And Significantly Undervalued: A Closer Look At Organon
Sep 10Organon Q2 2023 Earnings Review: Incremental Growth With A Slather Of Risk
Aug 10Organon & Co.: A Tough Spot To Be In Right Now
Jul 16Organon goes ex-dividend tomorrow
Feb 23Organon & Co. (NYSE:OGN) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Feb 19Is There Anything Organic Or Interesting About Organon?
Feb 07Organon goes ex-dividend tomorrow
Nov 09Organon's (NYSE:OGN) Dividend Will Be $0.28
Nov 08Take Care Before Diving Into The Deep End On Organon & Co. (NYSE:OGN)
Nov 05Organon: Thoughts Ahead Of Q3 Earnings
Oct 31Organon: What Is The Recipe?
Aug 31Oragenics announces early toxicology data for intranasal COVID-19 vaccine
Aug 24Organon, Samsung Bioepis Humira biosimilar Hadlima high concentration dosage gets FDA nod
Aug 17Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28
Aug 07Financial Position Analysis
Short Term Liabilities: OGN's short term assets ($4.5B) exceed its short term liabilities ($2.8B).
Long Term Liabilities: OGN's short term assets ($4.5B) do not cover its long term liabilities ($9.3B).
Debt to Equity History and Analysis
Debt Level: OGN's net debt to equity ratio (5522.2%) is considered high.
Reducing Debt: OGN's debt to equity ratio has increased from 2.5% to 6011.1% over the past 5 years.
Debt Coverage: OGN's debt is not well covered by operating cash flow (12.3%).
Interest Coverage: OGN's interest payments on its debt are not well covered by EBIT (2.6x coverage).